Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Medicenna Therapeutics Corp. (MDNAF) had Normalized Pre-Tax Income of $-3.09M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-3.09M |
|
-- |
|
-- |
|
$4.24M |
|
$-4.24M |
|
$1.16M |
|
$-3.09M |
|
|
Normalized Pre-Tax Income |
$-3.09M |
$-3.09M |
|
$-3.09M |
|
$-3.09M |
|
$-3.09M |
|
$-4.24M |
|
$-4.23M |
|
83.19M |
|
83.19M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$6.02M |
|
$0.00M |
|
$0.10M |
|
$6.12M |
|
$3.96M |
|
-- |
|
$0.37M |
|
$4.32M |
|
$1.80M |
|
$1.76M |
|
$1.80M |
|
83.42M |
|
| Cash Flow Statement Financials | |
$-12.97M |
|
$0.00M |
|
$-0.01M |
|
$17.98M |
|
$4.52M |
|
$-13.45M |
|
$1.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.52 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-171.82% |
|
-175.13% |
|
-50.44% |
|
-171.82% |
|
$0.02 |
|
$-0.16 |
|
$-0.16 |
|